Mereo Halts Plans For US Listing

 
• By Lucie Ellis-Taitt

Mereo BioPharma has withdrawn its Nasdaq public offering, which had a target of raising $80m, because of ‘challenging and volatile’ market conditions in the US.

Dollar bills
Mereo cites decline of the Nasdaq Biotech Index as one of its reasons for stepping away from a US listing • Source: Shutterstock

More from Strategy

More from Business